PWSA Blog

Ask Nurse Lynn: Growth Hormone: Daily vs Weekly Injections

Question:

Female, 8 years old, imprinting subtype

Hi! My daughter is currently taking omnitrope, but I stumbled upon skytrofa. I like that it’s a once-weekly injection, is preservative free and has shown a higher growth increase in trials for kids with growth hormone deficiency. I asked my daughter’s endocrinologist about it and was immediately shut down, being told it’s not FDA approved for PWS, only for pediatric growth hormone deficiency. My question is, isn’t growth hormone deficiency a secondary expression in the vast majority of PWS cases and is it worth pushing to have the doctor reconsider (or seek a second opinion)? If so, where do you recommend I start? Are there others you’re aware of that are currently taking skytrofa with PWS and what is the general consensus? Thanks. 

Nurse Lynn’s Response:

Your endocrinologist is correct that Skytrofa is currently FDA-approved only for children with pediatric growth hormone deficiency, it has not been approved for use in PWS. The daily growth hormone medications most used in PWS have been specifically studied and approved for use in children with PWS. That distinction is important because growth hormone therapy in PWS is used not only to address low growth hormone levels but also to improve body composition, muscle strength, and overall development, even in children who may not meet the classic criteria for growth hormone deficiency.

Many individuals with PWS do have relative growth hormone deficiency related to hypothalamic dysfunction, which is why growth hormone therapy is so beneficial. However, treatment in PWS is not simply replacing a missing hormone in the same way it is for isolated growth hormone deficiency. In classic pediatric GHD, the pituitary gland does not produce enough growth hormone, and treatment primarily replaces that hormone to support normal growth.

In PWS, the issue begins higher in the brain in the hypothalamus, which regulates multiple hormones and body systems. Because of this, children with PWS often have reduced or irregular growth hormone secretion rather than a straightforward deficiency, and growth hormone therapy is used for its broader metabolic and developmental benefits, not just height.

There have been very limited studies examining long-acting growth hormone medications specifically in individuals with PWS. Because people with PWS can have unique medical considerations, such as sleep-disordered breathing, differences in metabolism, and the need to closely monitor IGF-1 levels, many endocrinologists prefer to continue using daily growth hormone therapy until more safety and effectiveness data are available for the PWS population.

For now, daily growth hormone therapy remains the standard of care for individuals with PWS, supported by many years of research and clinical experience.

Resources:

Once-weekly SKYTROFA for children with pGHD | SKYTROFA® (lonapegsomatropintcgd)

Do you have a question for Nurse Lynn? Submit your question here:

    Please note that this question is optional and intended only for internal use to help improve our equity initiatives. We will not publish this information with your post.

Share this!

Scroll to top